A vaccine therapy called ELI-002 2P led to anti-cancer immune responses in a Phase 1 trial and showed potential for preventing disease relapses among people…
News
Enrollment is now open in a U.S. clinical trial testing the immune-modulating therapy CUE-102 in people with recurrent glioblastoma, an aggressive form of glioma…
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to SAR446523, an investigational therapy being developed by Sanofi for people with…
The U.S. Food and Drug Administration (FDA) granted fast track designation to birelentinib as a potential treatment for certain forms of blood cancer. The…
An independent committee has recommended that a clinical trial testing the experimental anticancer vaccine ELI-002 7P in people with pancreatic cancer should continue as…
The U.S. Food and Drug Administration (FDA) will allow Hemispherian to test its first-in-class experimental therapy for glioblastoma in a Phase 1 clinical trial.
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
Johnson & Johnson‘s Darzalex (daratumumab) is now the first approved treatment for high-risk smoldering multiple myeloma (SMM) in the European Union (EU). SMM…
More people in Canada with the rare blood cancer Ph+ CML — fully, Philadelphia chromosome-positive chronic myeloid leukemia — in the…
